Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Mauna Kea Technologies    MKEA   FR0010609263

MAUNA KEA TECHNOLOGIES (MKEA)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

MAUNA KEA TECH : MAUNA KEA TECHNOLOGIES ANNOUNCES CELLVIZIO'S VERY STRONG PRESENCE AT THREE MAJOR GASTROENTEROLOGY CONFERENCES IN THE USA, EUROPE AND JAPAN

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/15/2013 | 06:09pm CET
MAUNA KEA TECHNOLOGIES ANNOUNCES CELLVIZIO'S VERY STRONG PRESENCE AT THREE MAJOR GASTROENTEROLOGY CONFERENCES IN THE USA, EUROPE AND JAPAN 30 presentations dedicated to the benefits of optical biopsy at the same time on 3 continents Paris, Berlin, Tokyo, San Diego, October 15, 2013 - Mauna Kea Technologies (NYSE Euronext: MKEA FR0010609263), leader in the optical biopsy market and maker of Cellvizio, the fastest way to see cancer, today announced its strong participation in 3 major congresses around the world: the United European Gastroenterology Week (UEGW) in Berlin, the annual congress of the American College of Gastroenterology in San Diego, and the Japanese Digestive Disease Week in Tokyo. United European Gastroenterology Week (UEGW), Berlin, 12 to 16 October 2013

More than 20 study results on patient management optimization thanks to Cellvizio will be presented at this congress hosting 14,000 attendees, the most important and prestigious in gastroenterology in Europe. A large portion of these results will be on pancreatic cyst management with the AQ-Flex probe, which was recently cleared by FDA and launched in the USA.
A large number of attendees could also see a live demonstration of Cellvizio in the management of Barrett's Esophagus performed by Pr. Emmanuel Coron from CHU Nantes, France, from the Sana-Klinikum Lichtenhagen, where Cellvizio was used to orient the patient's therapeutic options.

Japanese Digestive Disease Week (JDDW), Tokyo, 8 to 12 October 2013

With more than 20 000 participants, this congress provided a strong exposure for Cellvizio to the Japanese market, a pioneering and very important one for digestive endoscopy. Several physicians from Japan and other Asian countries presented orally their results with Cellvizio on Asian populations, in particular on pancreatic cyst management.

Annual Congress of the American College of Gastroenterology (ACG), San Diego, 13 to 15 October 2013

Mauna Kea Technologies also has a strong presence at the ACG meeting, one of the most important for gastroenterology in the USA, the most important market for the Company today. Optical Biopsy was in the spotlight with more than 10 presentations as well as a hands-on training session on Cellvizio. Physicians could also discover how easy optical biopsy interpretation was thanks to a dedicated station.
Sacha Loiseau, CEO of Mauna Kea Technologies, declared: « The simultaneous presence of Mauna Kea Technologies on these 3 major gastroenterology congresses in Europe, Asia and the United-States, once more underlines the broad reach and the growing recognition of the value that Cellvizio optical biopsy brings to patients, physicians and healthcare systems around the world ».

About Mauna Kea Technologies

Mauna Kea Technologies is a global firm specializing in medical equipment used to carry out optical biopsies, and is market leader in endomicroscopy. The company designs, develops and sells innovative imaging tools that can detect cellular abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product, Cellvizio®, a confocal endomicroscopy system that uses a mini-probe, provides doctors and researchers with high-resolution cellular images of internal tissues. Large-scale, international multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early signs of disease and make immediate treatment decisions. Cellvizio was designed to help physicians make diagnoses, treat patients more effectively and reduce hospital costs, and is compatible with most types of endoscope. It has

1

received 510(k) authorization from the US Food and Drug Administration and the CE mark in Europe for use in gastrointestinal and pulmonary equipment.

For more information on Mauna Kea Technologies, please visit www.maunakeatech.com

Mauna Kea Technologies

Eric Cohen

V ice-President Finance

Tel: +33 (0)1 70 08 09 70

[email protected]

France and Europe

ALIZE RP

Caroline Carmagnol / Christian Berg

Tel: +33 (0)6 64 18 99 59 / +33 (0)1 70 22 53 86 [email protected] / [email protected]

NEWCAP

Investor Relations & Financial Communications

Florent Alba / Pierre Laurent Tel: +33 (0)1 44 71 94 94 [email protected]

2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MAUNA KEA TECHNOLOGIES
12/01 MAUNA KEA TECHNOLOGIES : Renews its Equity Financing Facility to Support its Dev..
10/18 MAUNA KEA TECHNOLOGIES : Appoints Olivier Regnard as Deputy CEO And Chief Financ..
09/15MAUNA KEA TECHNOLOGIES SAS : half-yearly earnings release
09/07 MAUNA KEA TECHNOLOGIES : Announces Strong Presence of Cellvizio at the OESO 14th..
08/24 MAUNA KEA TECHNOLOGIES : Patent Issued for Apparatus and Method for Brain Fiber ..
08/17 MAUNA KEA TECHNOLOGIES : Receives Specific U.S. FDA 510K Clearance for Use of Ce..
08/10 MAUNA KEA TECHNOLOGIES : Announces Peer-Reviewed Publication of Key Multicenter ..
07/11 MAUNA KEA TECHNOLOGIES : New Publication Confirms Benefits of Using Cellvizio fo..
07/11 MAUNA KEA TECHNOLOGIES : to Present at the JMP Securities 2017 Life Sciences Con..
03/28 MAUNA KEA TECH : New Peer-Reviewed Publication Reports Further External Validati..
More news
News from SeekingAlpha
10/19 Mauna Kea Technologies reports Q3 results
09/20 Mauna Kea Technologies reports 1H results
06/21 Mauna Kea Technologies SA (MKEAF) Presents At JMP Securities Life Sciences Co..
04/19 Mauna Kea Technologies reports Q1 results
03/23 Mauna Kea Technologies reports FY results
Financials (€)
Sales 2017 8,20 M
EBIT 2017 -9,95 M
Net income 2017 -10,2 M
Debt 2017 3,48 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 10,5x
EV / Sales 2018 8,63x
Capitalization 82,4 M
Chart MAUNA KEA TECHNOLOGIES
Duration : Period :
Mauna Kea Technologies Technical Analysis Chart | MKEA | FR0010609263 | 4-Traders
Technical analysis trends MAUNA KEA TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 3,45 €
Spread / Average Target -20%
EPS Revisions
Managers
NameTitle
Sacha Loiseau President, Chief Executive Officer & Director
Chris D. McFadden Chairman
John J. Soto Chief Operating Officer
Olivier Regnard Deputy Chief Executive & Financial Officer
François Lacombe Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MAUNA KEA TECHNOLOGIES39.07%97
THERMO FISHER SCIENTIFIC INC.33.21%76 376
DANAHER19.71%65 491
INTUITIVE SURGICAL81.55%41 579
ROYAL PHILIPS12.67%36 583
BOSTON SCIENTIFIC CORPORATION19.14%35 305